Melody Chang, R.Ph., says payers cover bispecific and CAR-T drugs but not the monitoring that lets community practices deliver them safely at lower cost.
|Articles|January 1, 2023
Most-Read Print Stories of 2022
Author(s)Briana Contreras
This year's most-read print stories from our monthly publication include 'Paxlovid Rebound: Rare But Real,' 'Diabetes Medications Find New Life as Weight-Loss Drugs,' 'Health Plans Prepare to Post Prices for Consumers,' and more.
Advertisement
- Paxlovid Rebound: Rare But Real
Mayo Clinic researchers reported today in the journal Clinical Infectious Diseases that less than 1% of patients at high risk for experiencing severe COVID-19 who were treated with Paxlovid (nirmatrelvir and ritonavir) experienced a second bout of COVID-19.Read more - Diabetes Medications Find New Life as Weight-Loss Drugs
Novo Nordisk’s Saxenda (liraglutide) and Wegovy (semaglutide) are leading the way for a new crop of drugs that reduce appetite. But their cost-effectiveness is in question, and many payers are saying no to coverage — for now.Read more
- Childhood Insomnia Symptoms Often Persist into Adulthood, Study Finds
Children with poor sleep had a 2.6-fold higher risk of developing adult insomnia, according to longitudinal research conducted by Penn State researchers.Read more - Multiple Sclerosis - Some Drugs New, Some Tried-and-True
The race is on to be the first-approved Bruton tyrosine kinase inhibitor. Meanwhile, trials are underway to test statins and metformin as treatments for multiple sclerosis.Read more - Health Plans Prepare to Post Prices for Consumers
Price-transparency rule allows insurers to cut MLR payments by using incentives to encourage consumers to choose low-cost, high-value providers.Read more
Advertisement
Related to this article
Continuous glucose monitoring cut mean A1C from 8.8% to 7.2% over 26 weeks in adults with type 2 diabetes not on insulin, 0.9 points more than routine care in the CONNECT trial.
American Oncology Network’s Melody Chang, R.Ph., says 18% of its first 70 outpatient bispecific patients had CRS, all low grade with no hospitalizations.
A screening program in eight countries found early-stage type 1 diabetes in about 1 in 350 children with no family history of the disease.
Healthcare leaders should be preparing now for important changes in prior authorization and other areas of healthcare.
UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say staff-driven ideas protect research independence in industry partnerships.
UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say research justifies services and opens doors to limited distribution drugs.
Garza, an expert on hidradenitis suppurativa at Johns Hopkins, says increasing incidence of the disease on the Japanese island of Okinawa offer some "tantalizing clues" about reasons for the rising incidence.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Apothecary Pharma recalls compounded tirzepatide and NAD+ vials over sterility concerns
2
More checks in the plus column for GLP-1s for obstructive sleep apnea | CHEST 2026
3
Algia Pharma completes investigational drug toxicology study for non-opioid acute pain regimen AlgiaPak
4
Rex Hoffman, M.D., on how a CMO balances competing priorities | HSES 2026
5